Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Eligible age
18–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old. Subjects will receive telavancin 10mg/kg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.
Sponsor: Aaron Cook
You may qualify if…
- ✓ Adult aged 18-85 years
- ✓ Actively draining ventriculostomy
You may not qualify if…
- ✕ history of hypersensitivity to telavancin or similar agents
- ✕ reduced renal function (estimated creatinine clearance \< 50/ml) at the time of consent
- ✕ severe anemia (hemoglobin \< 7gm/dl)
- ✕ vulnerable population (pregnant, prisoner)
- ✕ concomitant antimicrobial therapy
Where it's recruiting
Lexington
Source: ClinicalTrials.gov · NCT06119061 · last updated 2025-12-26